ENSIKLOPEDIA Cari Tekan Enter untuk memulai pencarian cepat. Kembali ke Ensiklopedia Arsip Wikipedia Indonesia Parsaclisib ParsaclisibInvestigational medication Pharmaceutical compoundParsaclisibClinical dataATC codeL01EM05 (WHO) Identifiers IUPAC name 4R)-4-[3-[(1S)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one CAS Number1426698-88-5PubChem CID86677874DrugBankDB14867ChemSpider64835232UNIIOS7097575KKEGGD11437ChEMBLChEMBL4297615Chemical and physical dataFormulaC20H22ClFN6O2Molar mass432.88 g·mol−13D model (JSmol)Interactive image SMILES CCOC1=C(C(=C(C=C1[C@H](C)N2C3=NC=NC(=C3C(=N2)C)N)Cl)F)[C@H]4CC(=O)NC4 InChI InChI=InChI=1S/C20H22ClFN6O2/c1-4-30-18-12(6-13(21)17(22)16(18)11-5-14(29)24-7-11)10(3)28-20-15(9(2)27-28)19(23)25-8-26-20/h6,8,10-11H,4-5,7H2,1-3H3,(H,24,29)(H2,23,25,26)/t10-,11-/m0/s1Key:ZQPDJCIXJHUERQ-QWRGUYRKSA-N Parsaclisib is an investigational drug that it being evaluated for the treatment of B-cell malignancies. It is a PI3Kδ (phosphoinositide 3-kinase) inhibitor.[1][2] References ↑ Gerds AT, Bartalucci N, Assad A, Yacoub A (August 2022). "Targeting the PI3K pathway in myeloproliferative neoplasms". Expert Review of Anticancer Therapy. 22 (8): 835–843. doi:10.1080/14737140.2022.2093192. hdl:2158/1351132. PMID 35763287. ↑ "Parsaclisib - Incyte Corporation". AdisInsight. Springer Nature Switzerland AG. vteTargeted cancer therapy / antineoplastic agents (L01)CI monoclonal antibodies ("-mab")Receptor tyrosine kinase ErbB: HER1/EGFR (Cetuximab Panitumumab) HER2/neu (Pertuzumab Trastuzumab (+hyaluronidase) Trastuzumab emtansine Trastuzumab deruxtecan Zanidatamab ) Others for solid tumors EpCAM (Catumaxomab Edrecolomab) VEGF-A (Bevacizumab) Leukemia/lymphoma lymphoid: CD3 (Glofitamab, Elranatamab, Mosunetuzumab), CD20 (Glofitamab Ibritumomab Mosunetuzumab Obinutuzumab Ofatumumab Rituximab Tositumomab), CD30 (Brentuximab), CD52 (Alemtuzumab) myeloid: CD33 (Gemtuzumab ozogamicin) Other Amivantamab (+hyaluronidase) Atezolizumab (+hyaluronidase) Avelumab Axatilimab Belantamab mafodotin Bermekimab Blinatumomab Cemiplimab Cosibelimab Daratumumab Dinutuximab beta Dostarlimab Durvalumab Elotuzumab Enfortumab vedotin Epcoritamab Inotuzumab ozogamicin Ipilimumab Isatuximab Linvoseltamab Loncastuximab tesirine Mirvetuximab soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab (+hyaluronidase, +relatlimab) Olaratumab Oportuzumab monatox Pembrolizumab (+berahyaluronidase alfa) Penpulimab Polatuzumab vedotin Prolgolimab Ramucirumab Retifanlimab Sabatolimab Sacituzumab govitecan Serplulimab Sugemalimab Tafasitamab Talquetamab Tarlatamab Teclistamab Tislelizumab Tisotumab vedotin Toripalimab Tremelimumab Zenocutuzumab Zolbetuximab Tyrosine kinase inhibitors ("-nib")Receptor tyrosine kinase ErbB: HER1/EGFR (Afatinib Aumolertinib Brigatinib Dacomitinib Erlotinib Gefitinib Icotinib Lazertinib Mobocertinib Olmutinib Osimertinib Rociletinib Sevabertinib Sunvozertinib Vandetanib) HER1/EGFR and HER2/neu Lapatinib Neratinib Tucatinib Zongertinib BRAF Dabrafenib Encorafenib Tovorafenib Vemurafenib RTK class III: C-kit and PDGFR (Avapritinib Axitinib Masitinib Pazopanib Ripretinib Sorafenib Sunitinib Toceranib) FLT3 (Lestaurtinib, Gilteritinib (AXL, ALK, LTK)) VEGFR Axitinib Cediranib Fruquintinib Lenvatinib Nintedanib Pazopanib Regorafenib Semaxanib Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK Alectinib Brigatinib Ceritinib Crizotinib Ensartinib Lorlatinib RET inhibitors: Entrectinib (ALK, ROS1, NTRK), Futibatinib (FGFR2), Infigratinib, Larotrectinib (NTRK), Pemigatinib (FGFR), Pralsetinib, Repotrectinib (ROS1, TRK, ALK), Selpercatinib (VEGFR, FGFR), Taletrectinib (ROS1), Vandetanib (VEGFR, EGFR). c-MET inhibitors: Cabozantinib (VEGFR), Capmatinib, Crizotinib (ALK) Non-receptor bcr-abl Asciminib Bosutinib Dasatinib Imatinib Nilotinib Ponatinib Radotinib Src (Bosutinib Dasatinib) Janus kinase (JAK) Baricitinib Fedratinib Filgotinib Lestaurtinib Momelotinib Pacritinib Ruxolitinib MAP2K (MEK) Binimetinib Cobimetinib Avutometinib (+defactinib) Mirdametinib Selumetinib Trametinib EML4-ALK Crizotinib Entrectinib Lorlatinib Bruton's (BTK) Acalabrutinib Ibrutinib Orelabrutinib Pirtobrutinib Rilzabrutinib Zanubrutinib Other fusion protein against VEGF (Aflibercept) proapoptotic peptide against ANXA2 and prohibitin (Adipotide) exotoxin against IL-2 (Denileukin diftitox) mTOR inhibitors Everolimus Ridaforolimus Sirolimus Temsirolimus hedgehog inhibitors Glasdegib Sonidegib Vismodegib CDK inhibitors Abemaciclib Dalpiciclib Palbociclib Ribociclib Trilaciclib KRAS inhibitors Adagrasib Sotorasib Pi3K inhibitors Alpelisib Copanlisib Duvelisib Idelalisib Inavolisib Parsaclisib Menin inhibitors Revumenib Ziftomenib Fibroblast growth factor receptor (FGFR) inhibitors Erdafitinib Futibatinib Infigratinib Pemigatinib Avapritinib Cabozantinib Capivasertib Capmatinib Defactinib (+avutometinib) Entrectinib Gilteritinib Larotrectinib Lenvatinib Masitinib Midostaurin Nintedanib Odronextamab Pazopanib Pexidartinib Pralsetinib Quizartinib Regorafenib Repotrectinib Ripretinib Selpercatinib Sitravatinib Sorafenib Sunitinib Surufatinib Tebentafusp Tepotinib Toceranib Tunlametinib Umbralisib Vandetanib Venetoclax Vimseltinib This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.vte
